Siemens Healthineers AG (OTCMKTS:SMMNY) Receives Average Rating of “Buy” from Analysts

Siemens Healthineers AG (OTCMKTS:SMMNY) has been given a consensus rating of “Buy” by the seven brokerages that are covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating, two have given a buy rating and three have issued a strong buy rating on the company.

Several equities analysts have weighed in on SMMNY shares. Citigroup reiterated a “buy” rating on shares of Siemens Healthineers in a report on Friday, January 23rd. Sanford C. Bernstein upgraded shares of Siemens Healthineers to a “strong-buy” rating in a report on Tuesday, January 13th. Deutsche Bank Aktiengesellschaft lowered shares of Siemens Healthineers from a “buy” rating to a “hold” rating in a research report on Thursday, December 4th. Zacks Research upgraded Siemens Healthineers from a “strong sell” rating to a “hold” rating in a report on Monday, January 12th. Finally, Royal Bank Of Canada started coverage on Siemens Healthineers in a research report on Wednesday, December 17th. They issued a “moderate buy” rating for the company.

Siemens Healthineers Price Performance

Shares of SMMNY stock opened at $21.24 on Thursday. Siemens Healthineers has a twelve month low of $20.85 and a twelve month high of $28.92. The company’s 50-day moving average price is $24.11 and its 200-day moving average price is $25.72.

Siemens Healthineers Company Profile

Siemens Healthineers AG is a leading global medical technology company that develops, manufactures and distributes a broad range of products and services for the healthcare sector. Headquartered in Erlangen, Germany, the company focuses on diagnostic and therapeutic imaging, in vitro diagnostics and advanced digital health solutions. As a spin-off from Siemens AG, Siemens Healthineers has leveraged decades of engineering expertise to establish a comprehensive portfolio that addresses critical needs in modern healthcare.

The company’s core offerings include magnetic resonance imaging (MRI), computed tomography (CT), X-ray and molecular imaging systems, as well as laboratory diagnostics equipment and point-of-care testing devices.